BCR-ABL and human cancer

Apoptosis, Cell Signaling, and Human Diseases

Volumn 1, Issue , 2007, Pages 3-33

  Pérez Caro, Maria ^a   Sánchez Garcia, Isidro ^b  

^a UNIVERSITY OF TUSCIA   (Italy)

^b CSIC   (Spain)

Author keywords

BCR ABL; cancer stem cells; chronic myelogenous leukemia (CML); disease progression; human cancer; imatinib mesylate; mouse models; stem cells; tyrosine kinase inhibition

Indexed keywords

EID: 84900605818     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-59745-200-7_1     Document Type: Chapter

References (192)

1. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science 1960;132:1497.
2. Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984;36(1):93-99.
3. Klucher KM, Lopez DV, Daley GQ. Secondary mutation maintains the transformed state in BaF3 cells with inducible BCR/ABL expression. Blood 1998;91(10):3927-3934.
4. Abelson HT, Rabstein LS. Influence of prednisolone on Moloney leukemogenic virus in BALB-c mice. Cancer Res 1970;30(8):2208-2212.
5. Ben-Neriah Y, Bernards A, Paskind M, Daley GQ, Baltimore D. Alternative 5' exons in c-abl mRNA. Cell 1986;44(4):577-586.
6. Van Etten RA, Jackson P, Baltimore D. The mouse type IV c-abl gene product is a nuclear protein, and activation of transforming ability is associated with cytoplasmic localization. Cell 1989;58(4):669-678.
7. Saglio G, Cilloni D. Abl: the prototype of oncogenic fusion proteins. Cell Mol Life Sci 2004;61(23):2897-2911.
8. Laneuville P. Abl tyrosine protein kinase. Semin Immunol 1995;7(4):255-266.
9. Woodring PJ, Hunter T, Wang JY. Regulation of F-actin-dependent processes by the Abl family of tyrosine kinases. J Cell Sci 2003;116(Pt 13):2613-2626.
10. Sawyers CL, McLaughlin J, Goga A, Havlik M, Witte O. The nuclear tyrosine kinase c-Abl negatively regulates cell growth. Cell 1994;77(1):121-131.
11. Yuan ZM, Shioya H, Ishiko T, et al. p73 is regulated by tyrosine kinase c-Abl in the apop-totic response to DNA damage. Nature 1999;399(6738):814-817.
12. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukaemia. Blood 2000;96:3343-3356.
13. Chissoe SL, Bodenteich A, Wang YF, et al. Sequence and analysis of the human ABL gene, the BCR gene, and regions involved in the Philadelphia chromosomal translocation. Genomics 1995;27(1):67-82.
14. McWhirter JR, Galasso DL, Wang JY. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol Cell Biol 1993;13(12):7587-7595.
15. Diekmann D, Brill S, Garrett MD, et al. Bcr encodes a GTPase-activating protein for p21rac. Nature 1991;351(6325):400-402.
16. Ma G, Lu D, Wu Y, Liu J, Arlinghaus RB. Bcr phosphorylated on tyrosine 177 binds Grb2. Oncogene 1997;14(19):2367-2372.
17. Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia pheno-type. Blood 1996;88(7):2375-2384.
18. Saglio G, Pane F, Martinelli G, Guerrasio A. BCR/ABL transcripts and leukemia pheno-type: an unsolved puzzle. Leuk Lymphoma 1997;26(3-4):281-286.
19. Clarkson B, Strife A. Linkage of proliferative and maturational abnormalities in chronic myelogenous leukemia and relevance to treatment. Leukemia 1993;7(11):1683-1721.
20. Ma G, Lu D, Wu Y, Liu J, Arlinghaus RB. Bcr phosphorylated on tyrosine 177 binds Grb2. Oncogene 1997;14(19):2367-2372.
21. Shuai K, Halpern J, ten Hoeve J, Rao X, Sawyers CL. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene 1996;13(2):247-254.
22. Ilaria RL, Jr, Van Etten RA. P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem 1996;271(49):31, 704-31, 710.
23. Skorski T, Kanakaraj P, Nieborowska-Skorska M, et al. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood 1995;86(2):726-736.
24. Franke TF, Kaplan DR, Cantley LC. PI3K: downstream AKTion blocks apoptosis. Cell 1997;88(4):435-437.
25. Sanchez-Garcia I, Grutz G. Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2. Proc Natl Acad Sci USA 1995;92(12):5287-5291.
26. de Groot RP, Raaijmakers JA, Lammers JW, Koenderman L. STAT5-Dependent CyclinD1 and Bcl-xL expression in Bcr-Abl-transformed cells. Mol Cell Biol Res Commun 2000;3(5):299-305.
27. Van Etten RA, Jackson PK, Baltimore D, Sanders MC, Matsudaira PT, Janmey PA. The COOH terminus of the c-Abl tyrosine kinase contains distinct F-and G-actin binding domains with bundling activity. J Cell Biol 1994;124(3):325-340.
28. Erratum in J Cell Biol 1994;124(5):865.
29. Salgia R, Li JL, Ewaniuk DS, et al. BCR/ABL induces multiple abnormalities of cytoskele-tal function. J Clin Invest 1997;100(1):46-57.
30. Gordon MY, Dowding CR, Riley GP, Goldman JM, Greaves MF. Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia. Nature 1987;328(6128):342-344.
31. Cortez D, Reuther G, Pendergast AM. The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells. Oncogene 1997;15(19):2333-2342.
32. Chopra R, Pu QQ, Elefanty AG. Biology of BCR-ABL. Blood Rev 1999;13(4):211-229.
33. Cogswell PC, Morgan R, Dunn M, et al. Mutations of the ras protooncogenes in chronic myelogenous leukemia: a high frequency of ras mutations in bcr/abl rearrangement-negative chronic myelogenous leukemia. Blood 1989;74(8):2629-2633.
34. Feinstein E, Cimino G, Gale RP, et al. p53 in chronic myelogenous leukemia in acute phase. Proc Natl Acad Sci USA 1991;88(14):6293-6297.
35. Sawyers CL. The role of myc in transformation by BCR-ABL. Leuk Lymphoma 1993; 11(Suppl 1):45-46.
36. Ahuja H, Bar-Eli M, Arlin Z, et al. The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia. J Clin Invest 1991;87(6):2042-2047.
37. Towatari M, Adachi K, Kato H, Saito H. Absence of the human retinoblastoma gene product in the megakaryoblastic crisis of chronic myelogenous leukemia. Blood 1991;78(9): 2178-2181.
38. Quesnel B, Preudhomme C, Fenaux Pp16ink4a gene and hematological malignancies. Leuk Lymphoma 1996;22(1-2):11-24.
39. Sill H, Goldman JM, Cross NC. Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia. Blood 1995;85(8):2013-2016.
40. Zion M, Ben-Yehuda D, Avraham A, et al. Progressive de novo DNA methylation at the bcr-abl locus in the course of chronic myelogenous leukemia. Proc Natl Acad Sci USA 1994;91(22):10, 722-10, 726.
41. Asimakopoulos FA, Shteper PJ, Krichevsky S, et al. ABL1 methylation is a distinct molecular event associated with clonal evolution of chronic myeloid leukemia. Blood 1999; 94(7):2452-2460.
42. Perez-Mancera PA, Gonzalez-Herrero I, Perez-Caro M, et al. SLUG in cancer development. Oncogene 2005;24(19):3073-3082.
43. Nieto MA, Sargent MG, Wilkinson DG, Cooke J. Control of cell behavior during vertebrate development by Slug, a zinc finger gene. Science 1994;264(5160):835-839.
44. Perez-Losada J, Sanchez-Martin M, Perez-Caro M, Perez-Mancera PA, Sanchez-Garcia I. The radioresistance biological function of the SCF/kit signaling pathway is mediated by the zinc-finger transcription factor Slug. Oncogene 2003;22(27):4205-4211.
45. Jiang R, Lan Y, Norton CR, Sundberg JP, Gridley T. The Slug gene is not essential for mesoderm or neural crest development in mice. Dev Biol 1998;98(2):277-285.
46. Sanchez-Martin M, Rodriguez-Garcia A, Perez-Losada J, Sagrera A, Read AP, Sanchez-Garcia I. SLUG (SNAI2) deletions in patients with Waardenburg disease. Hum Mol Genet 2002;11(25):3231-3236.
47. Sanchez-Martin M, Perez-Losada J, Rodriguez-Garcia A, et al. Deletion of the SLUG (SNAI2) gene results in human piebaldism. Am J Med Genet A 2003;122(2):125-132.
48. Inukai T, Inoue A, Kurosawa H, et al. SLUG, a ces-1-related zinc finger transcription factor gene with antiapoptotic activity, is a downstream target of the E2A-HLF oncoprotein. Mol Cell 1999;4(3):343-352.
49. Khan J, Bittner ML, Saal LH, et al. cDNA microarrays detect activation of a myogenic transcription program by the PAX3-FKHR fusion oncogene. Proc Natl Acad Sci USA 1999;96(23):13, 264-13, 269.
50. Perez-Losada J, Sanchez-Martin M, Rodriguez-Garcia A, et al. Zinc-finger transcription factor Slug contributes to the function of the stem cell factor c-kit signaling pathway. Blood 2002;100(4):1274-1286.
51. Chan LC, Karhi KK, Rayter SI, et al. A novel abl protein expressed in Philadelphia chromosome positive acute lymphoblastic leukaemia. Nature 1987;325(6105):635-637.
52. Melo JV, Myint H, Galton DA, Goldman JM. P190BCR-ABL chronic myeloid leukaemia: the missing link with chronic myelomonocytic leukaemia? Leukemia 1994;8(1):208-211.
53. Saglio G, Guerrasio A, Rosso C, et al. New type of Bcr/Abl junction in Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 1990;76(9):1819-1824.
54. Pane F, Frigeri F, Sindona M, et al. Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction). Blood 1996; 88(7):2410-2414.
55. Erratum in Blood 1997;89(11):4244.
56. Janssen JW, Ridge SA, Papadopoulos P, et al. The fusion of TEL and ABL in human acute lymphoblastic leukaemia is a rare event. Br J Haematol 1995;90(1):222-224.
57. Nilsson T, Andreasson P, Hoglund M, et al. ETV6/ABL fusion is rare in Ph-negative chronic myeloid disorders. Leukemia 1998;12(7):1167-1168.
58. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 1994;77(2):307-316.
59. Golub TR, Barker GF, Bohlander SK, et al. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc Natl Acad Sci USA 1995;92(11): 4917-4921.
60. Golub TR, Goga A, Barker GF, et al. Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia. Mol Cell Biol 1996;16(8):4107-4116.
61. Hannemann JR, McManus DM, Kabarowski JH, Wiedemann LM. Haemopoietic transformation by the TEL/ABL oncogene. Br J Haematol 1998;102(2):475-485.
62. Jousset C, Carron C, Boureux A, et al. A domain of TEL conserved in a subset of ETS proteins defines a specific oligomerization interface essential to the mitogenic properties of the TEL-PDGFR beta oncoprotein. EMBO J 1997;16(1):69-82.
63. Schwaller J, Frantsve J, Aster J, et al. Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo-and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes. EMBO J 1998;17(18):5321-5333.
64. McWhirter JR, Galasso DL, Wang JY. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol Cell Biol 1993;13(12):7587-7595.
65. Biernaux C, Sels A, Huez G, Stryckmans P. Very low level of major BCR-ABL expression in blood of some healthy individuals. Bone Marrow Transplant 1996;17(Suppl 3):S45-S47.
66. Sanchez-Garcia I. Consequences of chromosomal abnormalities in tumor development. Annu Rev Genet 1997;31:429-453.
67. Sanchez-Garcia I. Chromosomal Abnormalities, Cancer and Mouse Models: The critical role of translocation-associated genes in human cancer. Curr Genomics 2000;1:71-80.
68. Perez-Losada J, Gutierrez-Cianca N, Sanchez-Garcia I. Philadelphia-positive B-cell acute lymphoblastic leukemia is initiated in an uncommitted progenitor cell. Leuk Lymphoma 2001;42(4):569-576.
69. Bose S, Deininger M, Gora-Tybor J, Goldman JM, Melo JV. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood 1998;92(9):3362-3367.
70. Tordaro GJ, Green H. An assay for cellular transformation by SV40. Virology 1964; 23(1):117-119.
71. Lugo TG, Witte ON. The BCR-ABL oncogene transforms Rat-1 cells and cooperates with v-myc. Mol Cell Biol 1989;9(3):1263-1270.
72. Daley GQ, McLaughlin J, Witte ON, Baltimore D. The CML-specific P210 bcr/abl protein, unlike v-abl, does not transform NIH/3T3 fibroblasts. Science 1987;237(4814):532-535.
73. Daley GQ, Baltimore D. Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. Proc Natl Acad Sci USA 1988;85(23):9312-9316.
74. Sanchez-Garcia I, Grutz G. Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2. Proc Natl Acad Sci USA 1995;92(12):5287-5291.
75. Spencer A, Yan XH, Chase A, Goldman JM, Melo JV. BCR-ABL-positive lymphoblastoid cells display limited proliferative capacity under in vitro culture conditions. Br J Haematol 1996;94(4):654-658.
76. Carroll M, Tomasson MH, Barker GF, Golub TR, Gilliland DG. The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways. Proc Natl Acad Sci USA 1996;93(25):14, 845-14, 850.
77. Klucher KM, Lopez DV, Daley GQ. Secondary mutation maintains the transformed state in BaF3 cells with inducible BCR/ABL expression. Blood 1998;91(10):3927-3934.
78. Ruibao Ren. The molecular mechanism of chronic myelogenous leukemia and its therapeutic implications: studies in a murine model. Oncogene 2002;21:8629-8642.
79. Cobaleda C, Sanchez-Garcia I. In vivo inhibition by a site-specific catalytic RNA subunit of RNase P designed against the BCR-ABL oncogenic products: a novel approach for cancer treatment. Blood 2000;95(3):731-737.
80. Cobaleda C, Perez-Losada J, Sanchez-Garcia I. Chromosomal abnormalities and tumor development: from genes to therapeutic mechanisms. Bioessays 1998;20(11):922-930.
81. Nakano T, Kodama H, Honjo T. Generation of lymphohematopoietic cells from embryonic stem cells in culture. Science 1994;265(5175):1098-1101.
82. Era T, Witte ON. Regulated expression of P210 Bcr-Abl during embryonic stem cell differentiation stimulates multipotential progenitor expansion and myeloid cell fate. Proc Natl Acad Sci USA 2000;97(4):1737-1742.
83. Kyba M, Perlingeiro RC, Daley GQ. HoxB4 confers definitive lymphoid-myeloid engraft-ment potential on embryonic stem cell and yolk sac hematopoietic progenitors. Cell 2002;109(1):29-37.
84. Peters DG, Klucher KM, Perlingeiro RC, Dessain SK, Koh EY, Daley GQ. Autocrine and paracrine effects of an ES-cell derived, BCR/ABL-transformed hematopoietic cell line that induces leukemia in mice. Oncogene 2001;20(21):2636-2646.
85. McLaughlin J, Chianese E, Witte ON. In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome. Proc Natl Acad Sci USA 1987;84(18):6558-6562.
86. Sawyers CL, Gishizky ML, Quan S, Golde DW, Witte ON. Propagation of human blastic myeloid leukemias in the SCID mouse. Blood 1992;79(8):2089-2098.
87. Sawyers CL, Gishizky ML, Quan S, Golde DW, Witte ON. Propagation of human blastic leukemias in the SCID mouse. Blood 1992;79:2089-2098.
88. Cesano A, Hoxie JA, Lange B, Nowell PC, Bishop J, Santoli D. The severe combined immuno-deficient (SCID) mouse as a model for myeloid leukemias. Oncogene 1992;7:827-836.
89. Namikawa R, Ueda R, Kyoizumi S. Growth of human myeloid leukemia in the human marrow environment of SCID-hu mice. Blood 1993;82:2526-2536.
90. Shultz LD, Schweitzer PA, Christianson SW, et al. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol 1995;154:180-191.
91. Larochelle A, Vormoor J, Lapidot T, et al. Engraftment of immune-deficient mice with primitive hematopoietic cells from (3-thalassemia and sickle cell anemia patients: Implications for evaluating human gene therapy protocols. Hum Mol Genet 1995;4:163-172.
92. Cashman JD, Lapidot T, Wang JCY, et al. Kinetic evidence of the regeneration of multi-lineage hematopoiesis from primitive cells in normal human bone marrow transplanted into immunodeficient mice. Blood 1997;89:4307-4316.
93. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730-737.
94. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990;247(4944): 824-830.
95. Elefanty AG, Hariharan IK, Cory S. bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice. EMBO J 1990;9(4):1069-1078.
96. Kelliher MA, McLaughlin J, Witte ON, Rosenberg N. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc Natl Acad Sci USA 1990;87(17):6649-6653.
97. Zhang X, Ren R. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia. Blood 1998;92(10):3829-3840.
98. Pear WS, Miller JP, Xu L, et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 1998;92(10):3780-3792.
99. Hawley RG. High-titer retroviral vectors for efficient transduction of functional genes into murine hematopoietic stem cells. Ann NY Acad Sci 1994;716:327-330.
100. Cherry SR, Biniszkiewicz D, van Parijs L, Baltimore D, Jaenisch R. Retroviral expression in embryonic stem cells and hematopoietic stem cells. Mol Cell Biol 2000;20(20): 7419-7426.
101. Heisterkamp N, Jenster G, Kioussis D, Pattengale PK, Groffen J. Human bcr-abl gene has a lethal effect on embryogenesis. Transgenic Res 1991;1(1):45-53.
102. Honda H, Hirai H. Model mice for BCR/ABL-positive leukemias. Blood Cell Mol Dis 2001;27(1):265-278.
103. Huettner CS, Zhang P, Van Etten RA, Tenen DG. Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat Genet 2000;24(1):57-60.
104. Castellanos A, Pintado B, Weruaga E, et al. A BCR-ABL(p190) fusion gene made by homologous recombination causes B-cell acute lymphoblastic leukemias in chimeric mice with independence of the endogenous bcr product. Blood 1997;90(6):2168-2174.
105. Koschmieder S, Gottgens B, Zhang P, et al. Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemo-genesis. Blood 2005;105(1):324-334.
106. Schorpp-Kistner M, Wang ZQ, Angel P, Wagner EF. JunB is essential for mammalian placentation. EMBO J 1999;18(4):934-948.
107. Passegue E, Wagner EF, Weissman IL. JunB deficiency leads to a myeloproliferative disorder arising from hematopoietic stem cells. Cell 2004;119(3):431-443.
108. Holtschke T, Lohler J, Kanno Y, et al. Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell 1996;87(2):307-317.
109. Hao SX, Ren R. Expression of interferon consensus sequence binding protein (ICSBP) is downregulated in Bcr-Abl-induced murine chronic myelogenous leukemia-like disease, and forced coexpression of ICSBP inhibits Bcr-Abl-induced myeloproliferative disorder. Mol Cell Biol 2000;20(4):1149-1161.
110. Hoover RR, Gerlach MJ, Koh EY, Daley GQ. Cooperative and redundant effects of STAT5 and Ras signaling in BCR/ABL transformed hematopoietic cells. Oncogene 2001;20(41): 5826-5835.
111. Huettner CS, Zhang P, Van Etten RA, Tenen DG. Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat Genet 2000;24(1):57-60.
112. McCulloch EA. Stem cells in normal and leukemic hemopoiesis (Henry Stratton Lecture, 1982). Blood 1983;62(1):1-13.
113. Cline MJ. The molecular basis of leukemia. N Engl J Med 1994;330(5):328-336.
114. Trott, KR. Tumour stem cells: the biological concept and its application in cancer treatment. Radiother Oncol 1994;30:1-5.
115. Kummermehr, J, Trott, KR. In: Potten CS, ed., Stem Cells. 363-399 New York: Academic Press; 1997:363-399.
116. Cobaleda C, Gutierrez-Cianca N, Perez-Losada J, et al. A primitive hematopoietic cell is the target for the leukemic transformation in human philadelphia-positive acute lymphoblastic leukemia. Blood 2000;95(3):1007-1013.
117. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730-737.
118. Hope KJ, Jin L, Dick JE. Human acute myeloid leukemia stem cells. Arch Med Res 2003;34(6):507-514.
119. Mauro MJ, Druker BJ. Chronic myelogenous leukemia. Curr Opin Oncol 2001;13:3-7.
120. Jamieson CH, Ailles LE, Dylla SJ, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004;351(7):657-667.
121. Cozzio A, Passegue E, Ayton PM, Karsunky H, Cleary ML, Weissman IL. Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev 2003;17(24):3029-3035.
122. Gunsilius E, Duba HC, Petzer AL, et al. Evidence from a leukaemia model for maintenance of vascular endothelium by bone-marrow-derived endothelial cells. Lancet 2000;355:1688-1691.
123. Fang B, Zheng C, Liao L, et al. Identification of human chronic myelogenous leukemia progenitor cells with hemangioblastic characteristics. Blood 2005;105(7):2733-2740.
124. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorogenic breast cancer cells. Proc Natl Acad Sci USA 2003;100:3983-3988.
125. Singh SK. Identification of a cancer stem cell in human brain tumours. Cancer Res 2003;63:5821-5828.
126. Pardal R, Clarke MF, Morrison SJ. Applying the principles of stem-cell biology to cancer. Nat Rev Cancer 2003;3(12):895-902.
127. Silver RT, Woolf SH, Hehlmann R, et al. An evidence-based analysis of the effect of busul-fan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood 1999;94:1517-1536.
128. Goldman JM, Druker BJ. Chronic myeloid leukemia: current treatment options. Blood 2001;98(7):2039-2042.
129. Talpaz M, Kantarjian HM, McCredie KB, et al. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med 1986;314:1065-1069.
130. Salesse S, Verfaillie CM. BCR/ABL: from molecular mechanisms of leukemia induction to treatment of chronic myelogenous leukemia. Oncogene 2002;21(56):8547-8559.
131. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001;411:355-365.
132. Levitzki A, Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science 1995;267:1782-1788.
133. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ. The sequence of the human genome. Science 2001;291:1304-1351.
134. Uehara Y, Hori M, Takeuchi T, Umezawa H. Screening of agents which convert 'transformed morphology' of Rous sarcoma virus-infected rat kidney cells to 'normal morphology': identification of an active agent as herbimycin and its inhibition of intracellular src kinase. Jpn. J. Cancer Res 1985;76:672-675.
135. Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S. Genistein, a specific inhibitor of tyrosine specific protein kinases. J Biol Chem 1987;262:5592-5595.
136. Umezawa H, Imoto M, Sawa T, Isshiki K, Matsuda N. Studies on a new epidermal growth factor-receptor kinase inhibitor, erbstatin, produced by MH435-hF3. J Antibiot 1986;39: 170-173.
137. Carlo-Stella C, Dotti G, Mangoni L, Regazzi E, Garau D. Selection of myeloid progenitors lackingBCR/ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein. Blood 1996;88:3091-3100.
138. Kawada M, Tawara J, Tsuji T, Honma Y, Hozumi M. Inhibition of Abelson oncogene function by erbstatin analogues. Drugs Exp Clin Res 1993;19:235-241.
139. Yaish P, Gazit A, Gilon C, Levitzki A. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science 1988;242:933-935.
140. Levitzki A. Tyrosine kinases as targets for cancer therapy. Eur J Cancer 2002;38 (Suppl 5):S11-S18.
141. Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996;56(1): 100-104.
142. Kraker AJ, Hartl BG, Amar AM, Barvian MR, Showalter HD, Moore CW. Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol 2000;60(7):885-898.
143. Dorsey JF, Jove R, Kraker AJ, Wu J. The pyrido[2, 3-d]pyrimidine derivative PD180970 inhibits p210Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells. Cancer Res 2000;60(12):3127-3131.
144. Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005;7(2):129-141.
145. Savage DG, Antman KH. Imatinib mesylate-A new oral targeted therapy. N Engl J Med 2002;346(9):683-693
146. Druker BJ, Sawyers CL, Capdeville R, Ford JM, Baccarani M, Goldman JM. Chronic myelogenous leukemia. Hematology (Am Soc Hematol Educ Program). 2001;87-112. Review.
147. Mauro MJ, O'Dwyer M, Heinrich MC, Druker BJ. STI571: a paradigm of new agents for cancer therapeutics. J Clin Oncol 2002;20(1):325-334.
148. Okuda K, Weisberg E, Gilliland DG, Griffin JD. ARG tyrosine kinase activity is inhibited by STI571. Blood 2001;97:2440-2448.
149. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000;289(5486):1938-1942.
150. Fang G, Kim CN, Perkins CL, Ramadevi N, Winton E, Wittmann S, Bhalla KN. CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs. Blood 2000;96(6):2246-2253.
151. Deininger MW, Vieira S, Mendiola R, Schultheis B, Goldman JM, Melo JV. BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia. Cancer Res 2000;60(7):2049-2055.
152. Buchdunger E, O'Reilly T, Wood J. Pharmacology of imatinib (STI571). Eur J Cancer 2002;38(Suppl 5):S28-S36.
153. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-1037.
154. Druker BJ, O'Brien SG, Cortes J, Radich J. Chronic myelogenous leukemia. Hematology 2002;111-135. Review.
155. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344: 1038-1042.
156. Mitelman F. The cytogenetic scenario of chronic myeloid leukemia. Leuk Lymphoma 1993;11:11-15.
157. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293: 876-880.
158. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002;2:117-125.
159. Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A. Detection of BCRABL mutations in imatinib-treated CML patients is virtually always accompanied by clinical resistance and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003;102:276-283.
160. Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002;2(2):117-125.
161. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000;289(5486):1938-1942.
162. Azam M, Latek RR, Daley GQ. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 2003;112:831-843.
163. Hochhaus A, Kreil S, Corbin AS, La Rosee P, Muller MC. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002;16:2190-2196.
164. Takeda N, Shibuya M, Maru Y. The BCR-ABL oncoprotein potentially interacts with the xeroderma pigmentosum group B protein. Proc Natl Acad Sci USA 1999;96:203-207.
165. Tomlinson GE, Chen TT, StastnyVA, Virmani AK, Spillman MA. Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier. Cancer Res 1998;58:3237-3242
166. Deutsch E, Jarrousse S, Buet D, Dugray A, Bonnet ML. Down-regulation of BRCA1 in BCR-ABL-expressing hematopoietic cells. Blood 2003;101:4583-4588.
167. Spangrude GJ, Heimfeld S, Weissman IL. Purification and characterization of mouse hematopoietic cells. Science 1988;241:58-62.
168. Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002;99:319-325.
169. Chu S, Xu H, Shah NP, et al. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood 2005;05(5):2093-2098.
170. Bhatia R, Holtz M, Niu N, et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003;101(12):4701-4707.
171. Wisniewski D, Lambek CL, Liu C, Strife A, Veach DR. Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases. Cancer Res 2002;62: 4244-4255.
172. Huang M, Dorsey JF, Epling-Burnette PK, Nimmanapalli R, Landowski TH. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells. Oncogene 2002;21:8804-8816.
173. Huron DR, Gorre ME, Kraker AJ, Sawyers CL, Rosen N, Moasser MM. A novel pyrido-pyrimidine inhibitor of Abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants. Clin Cancer Res 2003;9:1267-1273.
174. Rapozzi V, Burm BE, Cogoi S, van derMarel GA, van Boom JH. Antiproliferative effect in chronic myeloid leukaemia cells by antisense peptide nucleic acids. Nucleic Acids Res 2002;30:3712-3721.
175. Wilda M, Fuchs U, Wossmann W, Borkhardt A. Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi). Oncogene 2002;21:5716-5724.
176. Szczylik C, Skorski T, Nicolaides NC, Manzella L, Malaguarnera L. Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides. Science 1991;253:562-565.
177. Lange W, Cantin EM, Finke J, Dolken G. In vitro in vivo effects of synthetic ribozymes targeted against BCR/ABL mRNA. Leukemia 1993;7:1786-1794.
178. Wright L, Wilson SB, Milliken S, Biggs J, Kearney P. Ribozyme-mediated cleavage of the bcr/abl transcript expressed in chronic myeloid leukemia. Exp Hematol 1993;21:1714-1718.
179. Choo Y, Sanchez-Garcia I, Klug A. In vivo repression by a site-specific DNA-binding protein designed against an oncogenic sequence. Nature 1994;372(6507):642-645.
180. Cobaleda C, Sanchez-Garcia I. RNase P: from biological function to biotechnological applications. Trends Biotechnol 2001;19(10):406-411.
181. Neckers L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 2002;8(4 Suppl):S55-S61.
182. Maloney A, Workman P. HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin Biol Ther 2002;2(1):3-24.
183. Nimmanapalli R, O'Bryan E, Bhalla K. Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts. Cancer Res 2001;61(5):1799-1804.
184. Perkins C, Kim CN, Fang G, Bhalla, KN. Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bclx(L). Blood 2000;95:1014-1022.
185. Yu C, Krystal G, Varticovksi L, McKinstry R, Rahmani M, Dent P, Grant S. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells. Cancer Res 2002;62(1):188-199.
186. Becker MW, Clarke MF SLUGging away at cell death. Cancer Cell 2002;2(4):249-251.
187. Inoue A, Seidel MG, Wu W, et al. Slug, a highly conserved zinc finger transcriptional repressor, protects hematopoietic progenitor cells from radiation-induced apoptosis in vivo. Cancer Cell 2002;2(4):279-288.
188. Castilla LH, Wijmenga C, Wang Q, et al. Failure of embryonic hematopoiesis and lethal hemorrhages in mouse embryos heterozygous for a knocked-in leukemia gene CBFB-MYH11. Cell 1996;87:687-696.
189. Corral J, Lavenir I, Impey H, et al. An Mll-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: a method to create fusion oncogenes. Cell.1996;85:853-861.
190. Yergeau DA, Hetherington CJ, Wang Q, et al. Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene. Nature Genet 1997;15:303-306.
191. Okuda T, Cai Z, Yang S, et al. Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dys-plastic hematopoietic progenitors. Blood 1998;91:3134-3143.
192. Forster A, Pannell R, Drynan LF, et al. The invertor knock-in conditional chromosomal translocation mimic. Nat Methods 2005;2:27-30.